Loading page
Loading page
Loading substance route
These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
There is considerable risk of physical harm when taking these combinations, they should be avoided where possible.
These combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
Triazolam is classified as habit-forming and susceptible to misuse and abuse. Its rapid onset of action and short half-life contribute to its abuse potential, though its relative obscurity compared to other fast-acting benzodiazepines limits diversion for recreational use.
Long-term use is associated with drug tolerance and physical dependence. Withdrawal symptoms can range from mild unpleasant feelings to a major withdrawal syndrome including stomach cramps, vomiting, muscle cramps, sweating, tremor, and in rare cases convulsions. Rebound insomnia can occur even after short-term, single-dose therapy.
Death can occur from triazolam overdose but is more likely when combined with other depressant drugs such as opioids, alcohol, or tricyclic antidepressants. Overdose symptoms include coma, respiratory depression, drowsiness, and slurred speech.
Long-term use of triazolam may cause cognitive impairment, anterograde amnesia, daytime sedation, and motor incoordination; residual hangover effects including psychomotor impairment may persist into the next day even after single doses.
Triazolam is FDA Pregnancy Category X and has the potential to cause birth defects when used during pregnancy.
Triazolam was withdrawn in the United Kingdom due to risk of psychiatric adverse drug reactions, particularly at higher dose ranges. Delirium, confusion, and amnesia have been reported. Abnormal dreams or nightmares occur rarely.
Seizures are listed as a potential symptom of overdose. Withdrawal from triazolam may cause convulsions in rare cases, particularly following abrupt discontinuation after prolonged use.
Triazolam was patented in 1970 and subsequently entered the pharmaceutical market in the United States in 1982 under the brand name Halcion. The drug gained widespread clinical adoption, and by 2017 it ranked as the 289th most commonly prescribed medication in the United States with over one…
UN Convention on Psychotropic Substances 1971 (Schedule IV)
Withdrawn from the market due to concerns about psychiatric adverse drug reactions associated with its use. Unlike in other countries where it remains available, triazolam is not prescribed in the UK despite being a medically used benzodiazepine elsewhere.
Controlled substance under the Controlled Substances Act (DEA Number 2887). Remains available for medical prescription use. Schedule IV classification indicates accepted medical use with relatively lower abuse potential compared to more restrictive schedules.
12 sources cited
